Literature DB >> 15618205

Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.

Pawel Goluszko1, Elzbieta Goluszko, Bogdan Nowicki, Stella Nowicki, Vsevolod Popov, Hui-Qun Wang.   

Abstract

The vaccination of C3H/HeJ mice with Escherichia coli Dr fimbrial antigen reduced mortality associated with an experimental urinary tract infection due to a homologous strain bearing Dr adhesin. Immune sera with high titers of anti-Dr antibody inhibited bacterial binding to bladders and kidneys but did not affect the rate of renal colonization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618205      PMCID: PMC538924          DOI: 10.1128/IAI.73.1.627-631.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Polarized entry of uropathogenic Afa/Dr diffusely adhering Escherichia coli strain IH11128 into human epithelial cells: evidence for alpha5beta1 integrin recognition and subsequent internalization through a pathway involving caveolae and dynamic unstable microtubules.

Authors:  J Guignot; M F Bernet-Camard; C Poüs; L Plançon; C Le Bouguenec; A L Servin
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Family of Escherichia coli Dr adhesins: decay-accelerating factor receptor recognition and invasiveness.

Authors:  B Nowicki; R Selvarangan; S Nowicki
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

3.  The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition.

Authors:  B Nowicki; A Labigne; S Moseley; R Hull; S Hull; J Moulds
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

4.  A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen.

Authors:  B Nowicki; J Moulds; R Hull; S Hull
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

5.  Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.

Authors:  B Pecha; D Low; P O'Hanley
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

6.  Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli.

Authors:  M Arthur; C E Johnson; R H Rubin; R D Arbeit; C Campanelli; C Kim; S Steinbach; M Agarwal; R Wilkinson; R Goldstein
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

7.  Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis.

Authors:  P Goluszko; S L Moseley; L D Truong; A Kaul; J R Williford; R Selvarangan; S Nowicki; B Nowicki
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

8.  Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.

Authors:  S Langermann; S Palaszynski; M Barnhart; G Auguste; J S Pinkner; J Burlein; P Barren; S Koenig; S Leath; C H Jones; S J Hultgren
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

9.  The afimbrial adhesive sheath encoded by the afa-3 gene cluster of pathogenic Escherichia coli is composed of two adhesins.

Authors:  M I Garcia; P Gounon; P Courcoux; A Labigne; C Le Bouguenec
Journal:  Mol Microbiol       Date:  1996-02       Impact factor: 3.501

10.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 2.  [Recurrent urinary tract infections in women. Virulence of pathogens and host reaction].

Authors:  T Oelschlaeger; R Fünfstück
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

Review 3.  Architects at the bacterial surface - sortases and the assembly of pili with isopeptide bonds.

Authors:  Antoni P A Hendrickx; Jonathan M Budzik; So-Young Oh; Olaf Schneewind
Journal:  Nat Rev Microbiol       Date:  2011-03       Impact factor: 60.633

Review 4.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.

Authors:  Christina A Sarkissian; Christopher J Alteri; Harry L T Mobley
Journal:  Vaccine       Date:  2019-07-15       Impact factor: 3.641

Review 6.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

Review 7.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

8.  Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection.

Authors:  Erin C Hagan; Harry L T Mobley
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

9.  Adhesive threads of extraintestinal pathogenic Escherichia coli.

Authors:  Esther-Maria Antão; Lothar H Wieler; Christa Ewers
Journal:  Gut Pathog       Date:  2009-12-10       Impact factor: 4.181

10.  Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Authors:  Christopher J Alteri; Erin C Hagan; Kelsey E Sivick; Sara N Smith; Harry L T Mobley
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.